GL1X · GenesisL1 explorer

Research workbench

HIV-1 protease in complex with symmetric inhibitor, BEA450

Analyse HIV-1 protease in complex with symmetric inhibitor, BEA450 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
1WBM
Type
protein
Length
198 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Pol protein (fragment)
UniProt
Q8Q3H0
Ligands
BLL
Pockets
1 · best druggability 0.72

Structure

x-ray diffraction · 1 distinct chain · 7% helix, 56% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BPol protein (fragment)protein997% helix, 56% strandQ8Q3H0

Ligands and binding sites

  • BLL · (2R,3R,4R,5R)-3,4-dihydroxy-N,N'-bis[(1s,2r)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-2,5-bis(2-phenylethyl)hexanediamide · ligand · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13470.720.8436BLL

Interfaces

1 interface between chains.

  • A–B · 1862 Ų buried · 37 hydrogen bonds · protein-protein

Compared structures

  • 1WBM · HIV-1 protease in complex with symmetric inhibitor, BEA450 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.